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Abstract
Nitric oxide (NO) is a vasoactive molecule that, by stimulated and functional vascular 
endothelial cells, is released to the lumen of the vessel and into the surrounding smooth 
muscle cells. Once in the lumen, NO is captured by red blood cells and scavenged inside 
through hemoglobin and derived as NO metabolites. The delivery ability of erythrocytes 
allowing the NO efflux also occurs. Manipulation of NO levels inside the erythrocyte 
through different external (acetylcholine, acetylcholinesterase inhibitors, fibrinogen and 
CD47 4N1K peptide) and internal (redox and protein phosphorylation levels) stimuli 
will be described. The values of NO efflux from the erythrocytes and its association with 
the data quantified in the hemorheology properties and in clinical parameters obtained 
from patients with vascular diseases will also be present. The in vivo animal experimen-
tal studies highlighting the ability of NO efflux (delivered) from the erythrocytes where 
is scavenged and its influence in inflammatory and hemorheological responses will be 
addressed. So, the aim of this chapter is to present the knowledge obtained about the NO 
signal transduction mechanism in erythrocytes and the association between erythrocyte 
availability in NO with clinical biomarkers obtained in inflammatory vascular diseases. A 
final question is raised—namely, could NO be considered a hemorheological parameter?
Keywords: erythrocyte, nitric oxide, deformability, intravital microscopy, 
pathophysiology
1. Introduction
Vascular endothelium cells behave like “meeting points” between white blood cells and medi-
ator factor participants in the steps of inflammatory response allowing “cross-talk” with blood, 
red blood cells (RBCs), platelets, fibrinogen, lipoproteins and other blood biomolecule compo-
nents [1]. Endothelial cells (ECs) under influence of mechanical, physical and chemical stimuli 
are prone to secrete vasoactive molecules into the lumen vessels and smooth muscle cells [2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The endothelium-derived factor secreted by vascular endothelial cells, known by its vaso-
dilator property, was further identified as nitric oxide (NO) by Robert F. Furchgott, Louis 
J. Ignarro and Ferid Murad who received the Nobel Prize in 1998 [3, 4].
Ignarro’s spectral analysis of hemoglobin (Hb) evidenced that when this biomolecule was 
exposed to endothelial cells’ stimulate by acetylcholine (ACh), NO is liberated and a shift of 
the Hb absorption curve occurs, establishing for the first time the NO binding to Hb and an 
indirect link between red blood cells (RBCs) and NO [4].
Other authors evidenced the ability of RBCs to rescue NO liberated from endothelium cells 
and the need to liberate it according the tissues oxygen partial pressure [5, 6]. Experiments 
conducted in vitro using RBCs under normoxia conditions submitting to low oxygen tension 
(hypoxia) showed liberation of oxygen and NO binding to deoxygenated hemoglobin demon-
strating consequently allosteric structure transitions of the Hb molecule [5]. The role of erythro-
cyte membrane band 3 protein into NO through erythrocyte was studied [5]. The bioavailability 
of RBCs in NO may be the trigger or the consequence of the involvement of the RBC’s hemoglo-
bin as the oxygen sensor [5, 6]. NO binds to oxygenated Hb in its thiol group of cysteine β93 at 
high-tissue oxygen pressure (PaO
2
) originating as S-nitrosohemoglobin (SNO-HbO
2
), while at 
low PaO
2,
 NO binds to the iron ion of the hemoglobin; heme group generates nitrosylhemoglo-
bin molecules [7, 8]. Regarding the efflux of NO from erythrocytes, the transfer of NO between 
SNO-HbO
2
 and the thiol group of band 3 protein was verified [9–11]. The transnitrosation reac-
tion could occur with the thiol group of other biomolecules [9–11]. Using inhibitors of pro-
tein tyrosine kinase (PTK) p72 syk, Src Lyn and of SHP-2 protein tyrosine phosphatase (PTP), 
in vitro studies have evidenced, respectively, band 3 protein phosphorylation and dephosphor-
ylation at tyrosine residues [12]. The dephosphorylation of band 3 is associated with oxyhemo-
globin and glycolytic enzymes binding which, upon band 3 phosphorylation, delivers oxygen 
and glyceraldehyde dehydrogenase, aldolase and phosphofructokinase closer to the cytosol 
[13]. Glutathione (GSH) is a redox biomolecule resulting from the reaction between the three 
peptides glycine, glutamic and cysteine showing its thiol group that can bind directly NO trans-
ferred from SNO-HbO
2,
 originating from nitrosothiol such as S-nitrosoglutathione (GSNO) [14]. 
The GSNO is a transient reservoir of NO because it is essential to be in its reduced state for 
the regeneration of NADPH to NADP levels of the erythrocyte. However, the inactivation of 
glutathione reductase induced by oxidative stress influences the concentration of GSH which is 
needed for regeneration of oxidized proteins [15]. For instance, dithiothreitol (DTT) is a thiol-
reducing agent capable of regenerating disulfide-containing proteins and establishing an inter-
changeable thiol-disulfide reaction with glutathione [16]. Beyond that, DTT’s presence induces 
changes on enzyme activity states, for example, of the PTP and PTK [17].
If auto-oxidation of hemoglobin occurs the peroxide anion will be produced, which gener-
ates peroxynitrite after reaction with NO [18]. The decomposition of peroxynitrite molecules 
leads to nitrite (NO2−) and nitrate (NO3−) which are designated NO derivative molecules (NOx) 
whose concentrations are changed by external RBC-binding biomolecules as shown [19, 20]. 
It was evidenced that NO release from SNOHb could bind to thiol groups and be exported 
from RBCs as nitrosothiol or may be so as oxidation generates nitrate [19]. The NO in the 
presence of oxyhemoglobin molecules induces methemoglobin and nitrate formation [20]. 
The hemoglobin reductase with the NADH produced in the glycolytic pathway maintains the 
methemoglobin concentration [21].
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Endothelial cells and lymphocytes are able, by the participation of choline acetyltransferase, 
to synthesize ACh which is released into the plasma through vesicular acetylcholine trans-
porter [22–24].
Depending on the degree of endothelium integrity the circulating ACh induced vasodilation 
or vasoconstriction according to the amount of nitric oxide synthesized and released [3]. The 
NO released from endothelial cells and platelets is scavenged by erythrocyte and blood cell-
free hemoglobin [25]. In order to identify the signal transduction mechanism of the erythro-
cyte ability to scavenge or deliver NO, in vitro studies mimicking normal and inflammatory 
conditions were performed and are presented in the next section. This section also includes 
ex vivo studies showing the quantification of the NO efflux values, performed with RBCs 
obtained from blood samples of healthy donors and patients with vascular inflammatory dis-
eases and their association with clinical biomarkers. Also, in vivo studies’ conduct in animal 
models of hypertension and inflammation are included in the next section to show erythro-
cyte NO availability, contribution and association with inflammatory vascular diseases. From 
all data obtained and herein described we are able to conclude the erythrocyte NO transloca-
tion across the erythrocyte membrane as a hemorheological parameter.
2. Erythrocyte nitric oxide studies
2.1. In vitro
Erythrocyte membrane acetylcholinesterase (AChE) is a hydrolytic enzyme with a rare kinetic 
profile with an optimum substrate concentration (So) from on AChE activity decrease with the 
augment of its substrate ACh [26, 27]. At lower or higher So values, the AChE-ACh enzyme 
complex forms are active or the less active ones, respectively [26, 27].
Based on the fact that SNO-Hb and GSNO have been considered reservoirs of NO and ACh is 
an endogenous compound with vasoactive properties, present in blood circulation, we raised 
three questions, whether ACh induces changes on erythrocyte deformability, if there is NO 
inside erythrocyte and whether it could be mobilized to the outside. In order to answer these, 
human erythrocyte suspensions, in the presence of ACh, were loaded with the permeable non-
fluorescent probe diamine fluorescein-2 diacetate (DAF-2 Da). Intra-erythrocyte fluorescence 
intensity of triazolofluorescein (DAF-2 T) was visualized, by fluorescence microscopy, as a 
result of the reaction between NO and the 4, 5- diamine fluorescein [28]. So, inside the eryth-
rocyte, there is NO when stimulated with ACh and also there is an increase in the levels of 
NO2− and NO3− [28]. When erythrocytes are in the presence of ACh, erythrocyte deformability, 
during the impairment of oxygen hemoglobin affinity and of erythrocyte aggregation (EA), 
has been verified [29]. The presence of an active complex (AChE-ACh) in red blood cells is able 
to trigger band 3 protein phosphorylation when PTP is inhibited, with a higher mobilization of 
NO-derived metabolites [30]. This complex is unable to induce band 3 phosphorylation upon 
p53/56lyn and p72syk inhibition, providing a lower degree of NO efflux and NOx mobilization 
[30]. This mobilization is enhanced with phosphorylated but not a dephosphorylated band 
3 protein. The maximum translocation of NO efflux from RBC achieved upon acetylcholine 
stimulation and band 3 phosphorylation was related to the higher levels of the methemoglobin, 
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[L-lactate], concentration ratio between cyclic guanylyl cyclase (cGMP) and cyclic adenosine 
monophosphate (cAMP) and lower oxygen affinity to hemoglobin value and of oxyhemoglo-
bin concentration [30]. At variance, the effect of the AChE inhibitor velnacrine maleate (VM) 
induced a higher degree of [NO] efflux/[NOx] mobilization through the AChE-VM inhibitor 
complex in the presence of p53/56lyn and p72syk inhibitors [30]. When in the case of eryth-
rocyte membrane band 3 protein dephosphorylated state, the inactive complex form of the 
AChE promotes higher NO efflux than the AChE active complex form [30]. But the opposite 
was observed with erythrocyte membrane band 3 protein phosphorylation [30]. When experi-
ments were done with the AChE strong inhibitor, VM, an almost inactive complex, results and 
induces lower NO efflux from erythrocytes and higher GSNO and peroxynitrite concentration 
values than those obtained with the active complex form AChE-ACh [30].
Additional studies were performed taking into account the identification of the type of a G-protein 
involved in the erythrocyte ACh/NO signaling pathway. It was evidenced that at the N-terminal 
band 3 protein domain only Gαi1/2 binds. Gαi1/2 and the Gβ are associated with band 3 protein at the 
C-terminal site domain independently of the band 3 phosphorylation degree [31]. This chapter 
confirmed our previous hypothesis of the potential involvement of a heterotrimeric G protein in 
signal events mediated by the erythrocyte membrane AChE-ACh complex or AChE-inhibitor 
complex band 3 protein interactions with the participation of adenylyl cyclase inhibition [20, 31].
The quantification of NO efflux from the erythrocyte was assessed, by the first time for us, 
using the amino-IV sensor by the amperometric method which is described [32, 33]. The nitric 
oxide release from RBC in presence of ACh is sense by an electrode which oxidize NO at the 
working platinum electrode, resulting on electric current. The redox current is proportional 
to the NO concentration outside the membrane and it was continuously monitored with a 
computer. The AChE-ACh active complex activates PKC which phosphorylates PTP and PTK 
switching them to inactive and activate enzymes states, resulting in band-3 protein phos-
phorylation by PTK active form without with consequently NO release [32–34].
Beyond the AChE’s strong inhibitor velnacrine, the moderate AChE inhibitor timolol was 
used, forming a less active AChE-timolol complex, and a lower erythrocyte efflux from NO 
was quantified in relation to those values obtained with AChE-ACh [35–37].
For the first time we evidenced that when erythrocytes were in the presence of ACh or timolol, 
the efflux of GSNO was lower with AChE-timolol than with AChE-ACh, both values being 
higher than in their absence [38].
It was evidenced by those in vitro studies that AChE’s active and less active molecular confor-
mations induce increased or decreased NO efflux from erythrocytes, respectively [38].
In the presence of SpermineNONOate, one among other NO donors, there is an increase in 
erythrocyte deformability and oxygen hemoglobin affinity (29).
The plasma levels of ACh increase in inflammatory pathologies like fibrinogen (Fib), a plasma 
molecule predominantly produced by the liver [39, 40]. From many years, it was recognized 
that Fib behavior in vascular domains, where blood circulation is under low shear stress, acts 
as the most influent molecule in erythrocyte aggregation (EA) [41]. The association between 
Fib and EA has been verified in several pathological conditions [42]. Only in this twenty-first 
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century was CD47 established as a binding target in the erythrocyte membrane for the soluble 
form of fibrinogen [43].
It was shown that for soluble Fib, in physiological concentrations, the NO efflux from erythro-
cytes decreased with increased GSNO, nitrite and nitrate levels [44]. The scavenging NO RBC 
ability to reduce efflux was surpassed showing normal values when both 4N1K (the CD47 
peptide analog of thrombospondin binding site) and high fibrinogen levels are present or 
when 4N1K is absent [45]. These data show the dependence of lower cyclic adenosine mono-
phosphate (cAMP) associated with adenylate cyclase (AC) inhibition by CD47Gαi [45]. When 
phosphorylation of the erythrocyte membrane protein band 3 is induced in the presence of 
high fibrinogen concentration and in the absence or presence of 4N1K, the NO efflux increases 
[46, 47]. The NO efflux from erythrocytes at high fibrinogen concentration is dependent on 
band 3 protein phosphorylation which was confirmed in the experiments where the erythro-
cyte casein kinase 2 (a cytosol protein that phosphorylates the band 3 protein) inhibitor was 
used, showing unchanged levels of NO efflux in relation to its absence [27, 48].
During inflammation high levels of both acetylcholine and fibrinogen are presented and normal 
values of NO efflux from erythrocytes have been observed in vitro [39, 49]. Besides, a higher NO 
efflux from RBC will be expected resulting of the presence of ACh and high fibrinogen concen-
tration, normal values were obtained; the AChE-ACh molecular conformational state activates 
PKC which inhibits PDE 3 with increase of cAMP concentration that normalize the lower levels 
of cAMP derived from the inhibition of AC [35, 38, 45, 49]. Interestingly, the presence of forskolin 
(activator of the enzyme AC) in an in vitro model of hyperfibrinogenemia did not change the 
levels of NO efflux from erythrocytes, because the PDE3 is functional to hydrolase cAMP [27, 48].
When stimulating the erythrocyte redox thiol status by loading dithiothreitol (DTT), there is 
a decreased NO efflux concomitant with increased levels of nitrite, nitrate and GSNO [50]. It 
is well known that dithiothreitol induces band 3 dephosphorylation and a dephosphorylated 
state accounts for the AChE inhibitors and fibrinogen effects on red cells [17, 30, 49].
High concentrations of oxidized LDL when in the presence of blood samples of healthy 
human erythrocytes increase its ability to scavenge NO [51]. The same behavior was obtained 
in another study conducted with blood samples taken from healthy humans and exposed or 
not (control aliquot) to two different concentrations of LDL/HDL; no changes in NO efflux 
values from the erythrocyte, no alterations on intra-erythrocyte peroxynitrite concentrations 
and an unaltered deformability profile, at all shear stresses, were observed. At variance the 
levels of intra-erythrocyte NO derivative molecules nitrite, nitrate and GSNO showed signifi-
cantly increased values when compared with control aliquots. The unchanged deformability 
values obtained at lower and high shear stresses for all treated blood sample aliquots with 
LDL/HDL are indicative of membrane stability, internal viscosity maintenance and normal 
interactions of membrane peripheral and cytoskeleton [52]. The absence of erythrocyte mem-
brane instability obtained in blood sample aliquots under LDL/HDL addition is confirmed 
by the unchanged nitrogen reactive species concentration of peroxynitrite, as evidence by 
the normal levels obtained for peroxynitrite is an index of auto-oxidation of oxyhemoglobin 
[52, 53]. The addition of different concentrations of the lipoprotein sub-fractions’ LDL/HDL 
seems not to favor hemoglobin auto-oxidation. Superoxide anion will be formed from the 
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auto-oxidation of hemoglobin, but without its generation plus unchanged values of peroxyni-
trite concentrations it was evidenced that when the thiol status of erythrocyte was maintained 
in normal range, no alterations were verified in erythrocyte deformability [50].
The NO efflux from erythrocytes is gender independent [54] at variance with higher women’s 
RBC AChE enzyme activity than men as previously evidenced [54]. Timolol maleate is a topi-
cally therapeutic drug used in glaucoma patients that, when incubated with blood samples 
of patients with this nerve optical disease, they did not induce significant differences in NO 
efflux from erythrocytes and nor in GSNO concentration values inside RBCs when compared 
to the absence of timolol in the blood aliquots of those erythrocytes [55]. Both NO efflux and 
GSNO values obtained were significantly higher than those quantified in blood samples of 
healthy persons [55]. Erythrocytes’ NO metabolism in glaucoma patients are not affected by 
timolol treatment [55].
The same amperometric NO sensor, mentioned above, was used in confluent human umbili-
cal endothelial cells (HUVECs) in which we have demonstrated the existence of membrane-
bound acetylcholinesterase and higher NO production in the presence of ACh in relation 
to velnacrine [56–58]. The activation of the signal transduction mechanism induced by the 
AChE-ACh active complex revealed high values of [cAMP] and [cGMP] which are lowered 
by the AChE-VM inactive complex [58].
2.2. Ex vivo
Hemorheology is the science which studies blood deformation and its components’ interaction 
with vessel walls, occurring inside blood vessels of macro and microcirculation. In the past, the 
longitudinal and follow-up clinical studies done, ex vivo, have as an objective the characteriza-
tion of the intravascular profile of different diseases according to hemorheological parameters 
and inflammatory factors [41, 48, 59]. To accomplish this aim, blood samples were taken from 
patients with acute myocardial infarction, glaucoma, Bechet, renal diseases whether submitted 
or not to chronic hemodialysis or kidney transplant and diabetic retinopathy degree, and an asso-
ciation between the laboratorial data and the clinical parameter values was observed [41, 48, 59].
Erythrocytes scavenge and liberate oxygen and NO at high and low local tissue oxygen partial 
pressure, respectively [60, 61]. Erythrocyte deformability is a biorheological influent factor on 
blood viscosity, cellular oxygenation and a biomarker of acute and chronic inflammation [62].
Patients with hypercholesterolemia, hypertension and renal transplant present lower ability 
to reversible change its shape (decrease erythrocyte deformability values) and higher val-
ues of NO efflux from erythrocytes  when stimulated with ACh [63]. In the same study, an 
inverse relationship between erythrocyte deformability values and NO efflux concentrations 
from erythrocytes obtained from blood samples of those patients, was evidenced [63]. In all 
samples lower values of NO efflux were verified in relation to those of healthy persons—what 
could be considered as a compensatory mechanism to avoid more wall vessel damage [63]. 
We will present in vivo studies later in this section.
Disturbed blood rheology in patients with systemic lupus erythematosus (SLE) and patients 
with rheumatoid arthritis (RA) that could contribute to atherosclerosis is described [64–66]. 
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So, a study was performed to evaluate the associations between hemorheology parameters 
including the erythrocyte NO rescue ability of RBCs and the cardiovascular risk factors, 
inflammatory parameters and subclinical atherosclerosis. Erythrocyte NO efflux was sig-
nificantly associated with both carotid intima-media thickness (cIMT) and the presence of 
plaques (negative association) and was an independent predictor of cIMT [67]. Erythrocyte 
NO production can be looked at as a compensatory mechanism [67]. As mentioned above, 
under low tissue oxygen partial tension, erythrocytes release NO bound to hemoglobin, pro-
moting vasodilation [61, 62]. Besides, NO could represent a protective factor against athero-
sclerosis; it could be produced in large amounts by the inducible nitric oxide synthase (iNOS) 
which is characteristic of the dysfunctional endothelium which combining with superoxide 
anion generates peroxynitrite molecules that have oxidant properties; this  NO derivative 
worse the dysfunctional endothelial wall hindering it to return to be functional [68].
The data of the hemorheological and inflammatory evaluations performed ex vivo in blood 
samples of women with SLE suggested greater risk of arterial thrombosis and prediction of 
higher mortality than humans with normal blood viscosity and fibrinogen values [67, 69]. 
Both SLE and RA patients showed high erythrocyte aggregation independent of the medica-
tion undertaken by SLE patients. This ex vivo study shows that hemorheological parameters 
are independently associated with the early stages of atherosclerosis in SLE and RA patients. 
Additionally, it documents disturbed and unfavorable hemorheological features in associa-
tion with disease activity and with traditional CV risk factors contributing to atherogenesis 
in inflammatory rheumatic diseases. So, the evaluation of NO and also of hemorheological 
parameters must be done in order to predict the development course of the autoimmune 
disease in RA and SLA patients [67].
In patients with amyotrophic lateral sclerosis (ALS) that is a neurodegenerative disease of the 
motor system, our aim was to assess RBCs’ biochemical and hemorheological parameters and 
identify novel biomarkers of one of the most painful and fast mortal disease after diagnosis 
[70]. The erythrocyte deformability and AChE activity of blood samples were increased in 
patients with ALS in comparison to healthy donors [70]. This ex vivo study conducted with 
blood samples of ALS patients showed lower values of NO efflux from RBCs and nitrites than 
those obtained in healthy humans [70]. Due to variability between the duration of this disease 
until death, the higher NO quartile values are associated with the worse respiratory function 
[70]. A positive relation of quartiles values were obtained between AChE enzyme activity and 
nitrites levels [70]. Both erythrocyte NO and AChE were suggested as biomarkers of ALS and 
further potential therapeutic targets [70].
Another very sad complex situation with high mortality covering healthy humans from all 
ages and under a variety of situations from a simple infection or travel accident to a post-
surgery complication is sepsis [71]. Several pathophysiological mechanisms from unbalanced 
pro−/anti -inflammatory, hypo and hyper-insulinemia, to hypo- and hyper-glycemia are 
simultaneously deregulated in intensive care units (ICUs). Follow-up studies carried out in 
ICU are urgently needed [71]. We have verified that in septic shock patients before dead, at 24 
in IUC showed higher efflux of NO from erythrocytes and worse blood circulation observed 
by hemodynamic parameters namely high unequal blood flow and high microvascular flow 
index quantified in sub lingual microcirculation [72].
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2.3. In vivo studies
The ACh molecule has a ubiquity property with an anti-inflammatory effect, decreasing leu-
kocytes’ adherence and plasma TNF-α concentration evidenced in an in vivo animal model of 
lipopolysaccharide-induced inflammation [73, 74].
The influence of NO on the hemoglobin affinity to oxygen and on biorheology properties of 
the erythrocytes was shown in healthy and in ill humans as described earlier. NO influx into 
erythrocytes induced by spermineNONOate or the efflux stimulates by ACh increased the 
reversible discocyte shape, or erythrocyte deformability, under shear stress values character-
istic of the microcirculation network as shown [29].
The angiotensin II AT1-receptor antagonist, valsartan, is able to restore, in hypertensive 
Sprague–Dawley rats which are LNAME dependent, their systolic blood pressure (SBP) to the 
physiological values, as well as normalize the whole blood viscosity (WBV) values increased 
during the hypertensive time [75]. The NO efflux from erythrocytes decreases in parallel to 
WBV and SBP returning to normal values after valsartan application [75]. Regarding erythro-
cyte deformability values that decreased during the hypertensive state of the animals, lower 
or normal values at lower and higher shear stress, respectively, were maintained after systolic 
blood pressure recovery by valsartan [75]. This in vivo animal experimental model of hyper-
tension demonstrated the relation between the endothelial cells and the erythrocytes’ avail-
ability of NO, beavering as a compensatory mechanism vascular disturbance [75]. This could 
be considered as an antagonist effect to the occurrence of reactive nitrogen species (RNS) and 
to the amplification of oxidative reactive species (ORS).
The in vivo mice model of acute inflammation induced by intra-scrotal injection of the plate-
let-activator factor (PAF, a phospholipid mediator of inflammation) showed that the NO efflux 
from erythrocytes decreases with acute-phase response development [76] The end of the acute 
inflammatory response visualized by intravital microscopy showed normalization of the num-
ber of labeled neutrophils rolling and adherent, rolling velocity and vessel diameter values [76]. 
NO normal values rewound with inflammation recover, besides the maintenance of decreased 
RBCs’ deformability [76]. There are PA receptors (PAF-R) constitutively present on platelets, leu-
kocytes and endothelial cells but are absent in red blood cells; besides, PAF stimulates the break-
down of sphingomyelin on RBCs in isotonic conditions [77]. Therefore, PAF may cause changes 
in the physicochemical structure of the erythrocyte membrane, which in turn may cause changes 
in RBC deformability maintained after the recovery of the initial phase of inflammatory response 
[77]. The NO efflux from erythrocyte behavior in this model of acute inflammatory response 
during 6 h in mice reinforces the idea of the NO rescue inside erythrocyte as a compensatory 
mechanism in low-grade or chronic inflammation of those diseases reported earlier [63, 77].
3. Conclusions
The nitric oxide mobilization inside or outside the erythrocyte is possible under either the 
action of the non-neuronal cholinergic components, acetylcholinesterase and acetylcholine, or 
the manipulation of band 3 protein phosphorylation degree. Higher NO efflux occurs under 
the influence of the AChE-ACh complex as well as, simultaneously, with the band 3 protein 
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phosphorylation. At variance, higher NO mobilization inside the erythrocytes happens under 
simultaneous influence of AChE-velnacrine and band 3 protein dephosphorylation.
At normal acetylcholine plasma levels, the erythrocyte NO efflux increases by a signal path-
way dependent of membrane band 3 protein phosphorylation, Giαβ protein, AC, acetylcholin-esterase enzyme activity and its molecular conformations, PKC and PD3.
The erythrocyte aggregation tendency is impaired by the presence of the AChE-ACh complex 
and is reinforced by higher thiol redox status inside the erythrocyte. The erythrocyte aggre-
gation is impaired by changes on band 3 phosphorylation/dephosphorylation equilibrium; 
besides, higher values are associated with a higher phosphorylation degree. On the contrary, 
ED increases in the presence of the AChE-ACh complex.
The ability of RBC to scavenge NO may be considered as a compensatory mechanism acting 
against the overproduced NO by the endothelial-inducible NO synthase when the vascular 
endothelium is dysfunctional [50].
Under unstimulated erythrocytes, GSNO efflux did not occur, and it is regarded as a poten-
tially therapeutical agent, acting as a store or donor of NO.
It is possible to modulate erythrocyte availability in NO by plasma fibrinogen in a nonlinear, 
dose-dependent manner in human erythrocytes. Lower intra-erythrocyte cAMP is an influent 
condition to the NO efflux in an in vitro model of hyperfibrinogenemia. These results may be 
considered a useful therapeutic approach for the storage of blood that is used in transfusions. 
Fibrinogen-C47-triggered erythrocyte GSNO and decreased NO efflux may, if verified in vivo, be 
associated with coagulopathy and hypotension under acute phase states. These effects show on 
NO-derived molecules, allowing intra-erythrocyte NO scavenging as a protector under inflam-
matory conditions as we evidenced in an animal model of acute inflammation and verified 
ex vivo in a vascular inflammatory disease with low-grade or chronic inflammation. An anti-reac-
tive nitrogen role can be attributed to ox-LDL for its contribution in the erythrocyte-scavenged 
ability for nitric oxide. From all studies reviewed here, we can suggest NO efflux or influx from 
or into RBCs and the internal mobilization between the NOx as a hemorheological parameter 
participating in the erythrocyte deformability in dependence of the structural protein conforma-
tions or phosphorylation degree components of the membrane or the internal RBC compartment.
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